This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Indications

Authoring team

Cisapride was licensed for:

  • symptoms and mucosal lesions associated with gastro-oesophageal reflux
  • impaired gastric motility symptom relief secondary to systemic conditions:
    • diabetes mellitus
    • autonomic neuropathy
    • systemic sclerosis
  • short-term management of non-ulcer dyspepsia
  • although cisapride is frequently used in children, particularly for the treatment of infantile gastro- oesophageal reflux, because of the risk of QT interval prolongation, cisapride is specifically contra - indicated in premature infants for up to 3 months after birth. Also in children up to the age of 12 years, there are insufficient data to support the use of cisapride.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.